Cover Image
Market Research Report

Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030

Published by ROOTS ANALYSIS Product code 927037
Published Content info 360 Pages
Delivery time: 1-2 business days
Price
Back to Top
Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030
Published: March 23, 2020 Content info: 360 Pages
Description

Example Insights:

In the last few years, over 600 clinical studies of various types of immune checkpoint modulation-based therapies, involving nearly 90,000 patients across different centers/hospitals, have been initiated worldwide.

Overview:

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2019, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years, across the globe. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, are still considered as the current standard of care. However, their efficacy is severely limited, especially when it comes to treating late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, are known to have a significant adverse impact on patients' quality of life. There are several targeted anti-cancer therapies that are available in the market and many are presently under development. Of these, immune checkpoint therapies have shown a lot of promise as viable and potent treatment options, capable of preventing tumor cells from evading immune surveillance. In 2011, Bristol-Myers Squibb's Yervoy® (ipilimumab), an anti-CTLA-4 monoclonal antibody, became the first FDA approved immune checkpoint inhibitor which was designed for the treatment of metastatic melanoma. Yervoy®, along with other first generation immune checkpoint inhibitors (targeting PD-1/PD-L1 and CTLA-4), soon demonstrated the ability to substantially prolong the lives of patients suffering from advanced stage tumors. However, despite the success of PD 1 / PD-L1 inhibitor drugs, there was a notable amount of resistance to treatment reported in certain groups of patients, which compromised the therapeutic potential of this relatively novel class of therapeutics.

Over the years, significant strides have been made in immune checkpoint modulation research, revealing several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are now being exploited for development of next generation immune checkpoint-based therapies. Moreover, clinical studies of combinatorial immune checkpoint blockade / co-stimulation, involving the newly identified checkpoints and known immune checkpoint inhibitor therapies, have demonstrated the potential to further augment therapeutic benefits. It is worth highlighting that these molecules have also shown to be capable of regulating immune tolerance and preventing / treating autoimmune disorders. Therefore, backed by promising clinical results and expanding applicability of therapies being investigated in late stages of development, the immune checkpoint inhibitors and stimulators market is poised to witness substantial growth in the foreseen future.

Scope of the Report:

The “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).
  • A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.
  • Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products) , featuring an overview of the company, its financial information (if available) , a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
  • An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of target immune checkpoints and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as grant amount, support period, type of grant application and number of disease indications under investigation.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to affiliated technology platforms and product candidates) , product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant types of deals.
  • An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for next generation immune checkpoint therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of grants and number of publications [B] a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.
  • An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of therapies under development, target disease indications, partnership activity and target portfolio.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for next generation immune checkpoint inhibitors and stimulators, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of next generation checkpoint modulator therapies and their likely selling price, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (colorectal cancer, head and neck cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, primary Sjögren's syndrome and systemic lupus erythematosus / lupus nephritis) [B] key immune checkpoint targets (B7-H3, CD38, CD40, CD47 and ICOS [C] mechanisms of action (inhibitory and costimulatory), [D] therapeutic modalities used (antibody fragment, monoclonal antibody and small molecule), [E] type of therapy (monotherapy, combination therapy and both), [F] route of administration (intravenous, subcutaneous and intracerebroventricular) and [G] key geographical regions (US, EU5, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for next generation immune checkpoint inhibitors and stimulators, in the short-midterm and long term.

Chapter 3 provides a general overview of cancer immunotherapy, highlighting important means of classification, focusing on next generation immune checkpoint modulators, including inhibitors and stimulators. The chapter lays emphasis on the role of immune checkpoints in cancer immunotherapy, including details on the various types of immune checkpoint targets, and their respective mechanisms of action. Further, it includes a discussion on the various challenges related to this class of therapeutics and highlights certain future perspectives.

Chapter 4 includes information on more than 300 molecules that are currently under development for the treatment of various cancer indications. It features a comprehensive analysis of pipeline molecules, highlighting, phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoint, mechanism of action (inhibitory or stimulatory, type of therapeutic modality (monoclonal antibody, antibody fragment, small molecule and others), route of administration, target therapeutic area(s), type of therapy (monotherapy, combination therapy and both). In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength.

Chapter 5 includes detailed pipeline analysis of the therapies being developed for CD47. The chapter features an analysis of the pipeline molecules on the basis of phase of development, therapeutic modality, route of administration, target disease indication, type of therapy and information on their therapy developers and highlighting leading developers.

Chapter 6 includes detailed pipeline analysis of the therapies being developed for 4-1BB. It features an analysis of the pipeline molecules on the basis of phase of development, therapeutic modality, route of administration, target disease indication, type of therapy and information on their therapy developers and highlighting leading developers.

Chapter 7 provides a detailed analysis of more than 590 completed, ongoing and planned clinical studies of various next generation immune checkpoint therapies, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, type of target immune checkpoint, target indication(s), key interventions, target therapeutic area(s), enrolled patient population and regional distribution of trials.

Chapter 8 provides detailed profiles of some of the leading stakeholders in this field (shortlisted based on number of pipeline products) . Each profile presents a brief overview of the company, its financial information (if available), product portfolio, recent collaborations and an informed future outlook.

Chapter 9 provides an analysis of more than 490 grants that were awarded to research institutes engaged in next generation immune checkpoint inhibitors and stimulators related projects, in the period between 2016 and 2019 (till November) based on the important parameters associated with grants, such as the year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of target immune checkpoint, and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, type of grant application and number of disease indications under investigation.

Chapter 10 features an elaborate analysis and discussion on the various collaborations and partnerships that have been inked amongst stakeholders in this domain, since 2017. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, and other agreements) that have been adopted by stakeholders in this domain. It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting most popular target immune checkpoint, and target disease indications.

Chapter 11 presents an insightful target competitiveness analysis, featuring a [A] three-dimensional bubble representation, highlighting the targets that are being evaluated for therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of publications and number of grants and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters.

Chapter 12 features an analysis on 14 big pharma companies, highlighting the key focus areas of these players across various parameters, such as products' stage of development, type of business model for the product under investigation, type of target immune checkpoint and target disease indications.

Chapter 13 features a detailed market forecast analysis, highlighting the likely growth of next generation immune checkpoint inhibitors and stimulators therapies till the year 2030. We have provided inputs on the likely distribution of the opportunity based on different target disease indications (colorectal cancer, head and neck cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, primary Sjögren's syndrome and systemic lupus erythematosus / lupus nephritis), targets immune checkpoints (B7-H3, CD38, CD40, CD47 and ICOS), type of therapeutic modality (antibody fragment, monoclonal antibody and small molecule), routes of administration (intravenous, subcutaneous and intracerebroventricular) and key geographical regions (US, EU5, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the next generation inhibitors and stimulators industry.

Chapter 15 is a collection of interview transcripts of discussions held with key stakeholders in this market.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table of Contents

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Cancer Immunotherapy
  • 3.3. Fundamentals of Cancer Immunotherapy
  • 3.4. Immune Checkpoint Modulators
  • 3.5. First Generation Immune Checkpoint Modulators
  • 3.6. Next Generation Immune Checkpoint Modulators
    • 3.6.1. Types of Next Generation Immune Checkpoint Modulators
  • 3.7. Challenges-related to Immune Checkpoint Modulation-based Therapy
  • 3.8. Future Perspectives

4. CURRENT MARKET LANDSCAPE: CLINICAL AND PRECLINICAL MOLECULES

  • 4.1. Chapter Overview
  • 4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
  • 4.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Pipeline Analysis
    • 4.3.1. Analysis by Phase of Development
    • 4.3.2. Analysis by Target Immune Checkpoint
    • 4.3.3. Analysis by Mechanism of Action
    • 4.3.4. Analysis by Therapeutic Modality
    • 4.3.5. Analysis by Route of Administration
    • 4.3.6. Analysis by Target Disease Indication
    • 4.3.7. Analysis by Therapeutic Area
    • 4.3.8. Analysis by Type of Therapy
    • 4.3.9. Funnel Representation: Analysis by Phase of Development, Mechanism of Action and Type of Therapy
  • 4.4. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size and Geographical Location
    • 4.4.3. Leading Developer Companies: Analysis by Number of Pipeline Therapies
    • 4.4.4. World Map Representation: Analysis by Geography

5. MARKET LANDSCAPE: THERAPIES TARGETING CD47

  • 5.1. Chapter Overview
  • 5.2. Next Generation Immune Checkpoint Inhibitors: Development Pipeline of CD47 Targeting Therapies
  • 5.3. Next Generation Immune Checkpoint Inhibitors: Pipeline Analysis of CD47 Targeting Therapies
    • 5.3.1. Analysis by Phase of Development
    • 5.3.2. Analysis by Therapeutic Modality
    • 5.3.3. Analysis by Route of Administration
    • 5.3.4. Analysis by Target Disease Indication
    • 5.3.5. Analysis by Type of Therapy
  • 5.4. Next Generation Immune Checkpoint Inhibitors: List of Companies Developing CD47 Targeting Therapies
    • 5.4.1. Analysis by Year of Establishment
    • 5.4.2. Analysis by Company Size and Geographical Location
    • 5.4.3. Leading Developers: Analysis by Number of Therapies
    • 5.4.4. World Map Representation: Analysis by Geography

6. MARKET LANDSCAPE: THERAPIES TARGETING 4-1BB

  • 6.1. Chapter Overview
  • 6.2. Next Generation Immune Checkpoint Stimulators: Development Pipeline of 4-1BB Targeting Therapies
  • 6.3. Next Generation Immune Checkpoint Stimulators: Pipeline Analysis of 4-1BB Targeting Therapies
    • 6.3.1. Analysis by Phase of Development
    • 6.3.2. Analysis by Therapeutic Modality
    • 6.3.3. Analysis by Route of Administration
    • 6.3.4. Analysis by Target Disease Indication
    • 6.3.5. Analysis by Type of Therapy
  • 6.4. Next Generation Immune Checkpoint Stimulators: List of Companies Developing 4-1BB Targeting Therapies
    • 6.4.1. Analysis by Year of Establishment
    • 6.4.2. Analysis by Company Size and Geographical Location
    • 6.4.3. Leading Developers: Analysis by Number of Therapies
    • 6.4.4. World Map Representation: Analysis by Geography

7. CLINICAL TRIAL ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Clinical Trial Analysis
    • 7.3.1. Analysis by Trial Registration Year
    • 7.3.2. Analysis by Trial Phase
    • 7.3.3. Analysis by Trial Recruitment Status
    • 7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
    • 7.3.5. Analysis by Study Design
    • 7.3.6. Analysis by Sponsor / Collaborator
    • 7.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
    • 7.3.8. Word Cloud: Key Focus Areas
    • 7.3.9. Analysis by Target Immune Checkpoint
    • 7.3.10. Analysis by Target Therapeutic Area
    • 7.3.11. Popular Interventions: Analysis by Number of Registered Trials
    • 7.3.12. Geographical Analysis by Number of Registered Trials
    • 7.3.13. Geographical Analysis by Trial Recruitment Status
    • 7.3.14. Geographical Analysis by Number of Patients Enrolled

8. COMPANY PROFILES: NEXT GENERATION INHIBITORS AND STIMULATORS

  • 8.1. Chapter Overview
  • 8.2. Bristol-Myers Squibb
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Next Generation Immune Checkpoint Therapeutics Portfolio
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Eli Lilly
    • 8.3.1. Company Overview
    • 8.3.2. Financial Information
    • 8.3.3. Next Generation Immune Checkpoint Therapeutics Portfolio
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. GlaxoSmithKline
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
    • 8.4.4. Recent Developments and Future Outlook
  • 8.4. Novartis
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. XOMA
    • 8.5.1. Company Overview
    • 8.5.2. Financial Information
    • 8.5.3. Next Generation Immune Checkpoint Therapeutics Portfolio
    • 8.5.4. Recent Developments and Future Outlook

9. ACADEMIC GRANTS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Analysis of Grants Awarded by the National Institutes of Health (NIH)
    • 9.3.1. Analysis by Year of Grant Award
    • 9.3.2. Analysis by Amount Awarded
    • 9.3.3. Analysis by Administering Institute Center
    • 9.3.4. Analysis by Funding Institute Center
    • 9.3.5. Analysis by Support Period
    • 9.3.6. Analysis by Funding Institute Center and Support Period
    • 9.3.7. Analysis by Type of Grant Application
    • 9.3.8. Analysis by Purpose of Grant Award
    • 9.3.9. Analysis by Grant Mechanism
    • 9.3.10. Word Cloud: Emerging Focus Areas
    • 9.3.11. Popular Target Immune Checkpoints: Analysis by Number of Grants
    • 9.3.12. Analysis of Grant Amount Awarded by Target Immune Checkpoints
    • 9.3.13. Analysis by Study Section Involved
    • 9.3.14. Analysis by Types of Recipient Organizations
    • 9.3.15. Popular Recipient Organizations: Analysis by Number of Grants
    • 9.3.16. Prominent Program Officers: Analysis by Number of Grants
    • 9.3.17. Regional Analysis of Recipient Organizations
  • 9.4. Grant Attractiveness Analysis

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Target Immune Checkpoint
    • 10.3.4. Analysis by Year of Partnership and Target Immune Checkpoint
    • 10.3.5. Analysis by Type of Partnership and Target Immune Checkpoint
    • 10.3.6. Analysis by Type of Partnership and Target Disease Indication
    • 10.3.7. Analysis by Year and Type of Partner
    • 10.3.8. Most Active Players: Analysis by Number of Partnerships
    • 10.3.9. Regional Analysis
    • 10.3.10. Intercontinental and Intracontinental Agreements

11. TARGET COMPETITIVENESS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors and Stimulators
    • 11.3.1. Four-Dimensional Bubble Analysis
    • 11.3.2 Five-Dimensional Spider Web Analysis

12. BIG PHARMA INITIATIVES

  • 12.1. Chapter Overview
  • 12.2. Big Pharma Initiatives Focused on Next Generation Immune Checkpoint
    • 12.2.1. Analysis by Number of Initiatives
    • 12.2.2. Analysis by Product Development Strategy
    • 12.2.4. Analysis by Target Immune Checkpoint Modulators
    • 12.2.5. Grid Representation: Analysis by Product Development Strategy and Target Immune Checkpoint
    • 12.2.6. Analysis by Therapeutic Area
      • 12.2.6.1. Heat Map: Big Pharma Initiatives Focused on Oncological Indications
      • 12.2.6.2. Heat Map: Big Pharma Initiatives Focused on Non-Oncological Indications

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030
  • 13.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Individual Product Sales Forecasts
    • 13.4.1. DARZALEX® (Janssen Pharmaceuticals)
      • 13.4.1.1. Target Patient Population
      • 13.4.1.2. Sales Forecast
    • 13.4.2. GSK3359609 (GlaxoSmithKline)
      • 13.4.2.1. Target Patient Population
      • 13.4.2.2. Sales Forecast
    • 13.4.3. RRx-001 (EpicentRx)
      • 13.4.3.1. Target Patient Population
      • 13.4.3.2. Sales Forecast
    • 13.4.4. SAR650984 (Sanofi)
      • 13.4.4.1. Target Patient Population
      • 13.4.4.2. Sales Forecast
    • 13.4.5. MGA271 (MacroGenics)
      • 13.4.5.1. Target Patient Population
      • 13.4.5.2. Sales Forecast
    • 13.4.6. Omburtamab (Y-mAbs Therapeutics)
      • 13.4.6.1. Target Patient Population
      • 13.4.6.2. Sales Forecast
    • 13.4.7. AMG557 (Amgen)
      • 13.4.7.1. Target Patient Population
      • 13.4.7.2. Sales Forecast
    • 13.4.8. APX005M (Apogenix)
      • 13.4.8.1. Target Patient Population
      • 13.4.8.2. Sales Forecast
    • 13.4.9. BI 655064 (Boehringer Ingelheim)
      • 13.4.9.1. Target Patient Population
      • 13.4.9.2. Sales Forecast
    • 13.4.10. Dapirolizumab Pegol (UCB Pharma)
      • 13.4.10.1. Target Patient Population
      • 13.4.10.2. Sales Forecast
  • 13.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region
    • 13.5.1. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, 2020-2030
    • 13.5.2. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Europe, 2020-2030
    • 13.5.3. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Asia-Pacific, 2020-2030
    • 13.5.4. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Rest of the World, 2020-2030
  • 13.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication
    • 13.6.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2020-2030
    • 13.6.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2020-2030
    • 13.6.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Hematological Malignancies, 2020-2030
    • 13.6.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2020-2030
    • 13.6.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2020-2030
    • 13.6.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2020-2030
    • 13.6.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-Oncological Indications, 2020-2030
  • 13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint
    • 13.7.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2020-2030
    • 13.7.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030
    • 13.7.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2020-2030
    • 13.7.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2020-2030
    • 13.7.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2020-2030
  • 13.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action
    • 13.8.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030
    • 13.8.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2020-2030
  • 13.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality
    • 13.9.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Antibody Fragments, 2020-2030
    • 13.9.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibodies, 2020-2030
    • 13.9.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecule Drugs, 2020-2030
  • 13.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy
    • 13.10.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030
    • 13.10.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030
    • 13.10.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2020-2030
  • 13.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration
    • 13.11.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2020-2030
    • 13.11.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030
    • 13.11.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2020-2030

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1. Mechanisms of Action of Immunotherapies
  • Figure 3.2. Types of Immune Checkpoint Targets
  • Figure 4.1. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Phase of Development
  • Figure 4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Immune Checkpoint
  • Figure 4.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Mechanism of Action
  • Figure 4.4. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Modality
  • Figure 4.5. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Route of Administration
  • Figure 4.6. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Disease Indication
  • Figure 4.7. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Area
  • Figure 4.8. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Type of Therapy
  • Figure 4.9. Funnel Representation: Distribution by Phase of Development, Mechanism of Action and Type of Therapy
  • Figure 4.10. Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Year of Establishment
  • Figure 4.11. Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Company Size and Geographical Location
  • Figure 4.12. Leading Developer Companies: Distribution by Number of Pipeline Therapies
  • Figure 4.13. World Map Representation: Distribution by Geography
  • Figure 5.1. Immune Checkpoint Inhibitors for CD47: Distribution by Phase of Development
  • Figure 5.2. Immune Checkpoint Inhibitors for CD47: Distribution by Therapeutic Modality
  • Figure 5.3. Immune Checkpoint Inhibitors for CD47: Distribution by Route of Administration
  • Figure 5.4. Immune Checkpoint Inhibitors for CD47: Distribution by Target Disease Indication
  • Figure 5.5. Immune Checkpoint Inhibitors for CD47: Distribution by Type of Therapy
  • Figure 5.6. Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Year of Establishment
  • Figure 5.7. Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Company Size and Geographical Location
  • Figure 5.8. Leading Developers: Distribution by Number of Pipeline Therapies for CD47
  • Figure 5.8. World Map Representation: Distribution by Geography
  • Figure 6.1. Immune Checkpoint Stimulators for 4-1BB: Distribution by Phase of Development
  • Figure 6.2. Immune Checkpoint Stimulators for 4-1BB: Distribution by Therapeutic Modality
  • Figure 6.3. Immune Checkpoint Stimulators for 4-1BB: Distribution by Route of Administration
  • Figure 6.4. Immune Checkpoint Stimulators for 4-1BB: Distribution by Target Disease Indication
  • Figure 6.5. Immune Checkpoint Stimulators for 4-1BB: Distribution by Type of Therapy
  • Figure 6.6. Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Year of Establishment
  • Figure 6.7. Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Company Size and Geographical Location
  • Figure 6.8. Leading Developers: Distribution by Number of Therapies for 4-1BB
  • Figure 6.9. World Map Representation: Distribution by Geography
  • Figure 7.1. Clinical Trial Analysis: Scope and Methodology
  • Figure 7.2. Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
  • Figure 7.3. Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 7.4. Clinical Trial Analysis: Distribution by Trial Status
  • Figure 7.5. Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Figure 7.6. Clinical Trial Analysis: Distribution by Study Design
  • Figure 7.7. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 7.8. Leading Industry Sponsors: Distribution by Number of Registered Trials
  • Figure 7.9. Word Cloud: Key Focus Areas
  • Figure 7.10. Clinical Trial Analysis: Distribution by Target Immune Checkpoint
  • Figure 7.11. Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Figure 7.12. Popular Interventions: Distribution by Number of Registered Trials
  • Figure 7.13. Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Figure 7.14. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
  • Figure 7.15. Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Figure 8.1. Bristol-Myers Squibb: Annual Revenues, 2014- 9M 2019(USD Billion)
  • Figure 8.2. Eli Lilly: Annual Revenues, 2014- 3M 2019(USD Billion)
  • Figure 8.3. GlaxoSmithKline: Annual Revenues, 2014-2019(USD Billion)
  • Figure 8.4. Novartis: Annual Revenues, 2014-6M 2019(USD Billion)
  • Figure 8.5. XOMA: Annual Revenues, 2014-9M 2019(USD Million)
  • Figure 9.1. Grant Analysis: Distribution by Year of Grant Award, 2016-2019
  • Figure 9.2. Grant Analysis: Distribution by Amount Awarded(USD Million), 2016-2019
  • Figure 9.3. Grant Analysis: Distribution by Administering Institute Center
  • Figure 9.4. Grant Analysis: Distribution by Funding Institute Center
  • Figure 9.5. Grant Analysis: Distribution by Support Period
  • Figure 9.6. Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Figure 9.7. Grant Analysis: Distribution by Type of Grant Application
  • Figure 9.8. Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 9.9. Grant Analysis: Distribution by Grant Mechanism
  • Figure 9.10. Word Cloud: Emerging Focus Areas
  • Figure 9.11. Popular Target Immune Checkpoints: Distribution by Number of Grants
  • Figure 9.12. Grant Analysis: Distribution of Grant Amount Awarded by Target Immune Checkpoints
  • Figure 9.13. Grant Analysis: Distribution by Study Section Involved
  • Figure 9.14. Grant Analysis: Distribution by Types of Recipient Organizations
  • Figure 9.15. Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 9.16. Prominent Program Officers: Distribution by Number of Grants
  • Figure 9.17. Grant Analysis: Distribution by Recipient Organizations
  • Figure 9.18. Grant Analysis: Categorizations based on Weighted Attractiveness Scores
  • Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
  • Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2020.
  • Figure 10.4. Partnerships and Collaborations: Distribution by Target Immune Checkpoint
  • Figure 10.5. Partnerships and Collaborations: Distribution by Year of Partnership and Target Immune Checkpoint
  • Figure 10.6. Partnerships and Collaborations: Distribution Type of Partnership and Target Immune Checkpoint
  • Figure 10.7. Partnerships and Collaborations: Distribution by Type of Partnership and Target Disease Indication
  • Figure 10.8. Partnerships and Collaborations: Distribution by Year and Type of Partner
  • Figure 10.9. Most Active Players: Distribution by Number of Partnerships
  • Figure 10.10. Partnership and Collaborations: Regional Distribution
  • Figure 10.11. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 11.1. Target Competitiveness Analysis: Four-Dimensional Bubble Analysis
  • Figure 11.2. Target Competitiveness Analysis: Five-Dimensional Spider Web Analysis
  • Figure 12.1. Big Pharma Initiatives: Distribution by Number of Initiatives
  • Figure 12.2. Big Pharma Initiatives: Distribution by Product Development Strategy
  • Figure 12.3. Big Pharma Initiatives: Distribution by Target Immune Checkpoint
  • Figure 12.4. Grid Representation: Distribution by Product Development Strategy and Target Immune Checkpoint
  • Figure 12.5. Big Pharma Initiatives: Distribution by Therapeutic Area
  • Figure 12.6. Heat Map: Big Pharma Initiatives Focused on Oncological Indications
  • Figure 12.7. Heat Map: Big Pharma Initiatives Focused on Non-Oncological Indications
  • Figure 13.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030(USD Million)
  • Figure 13.2. DARZALEX®: Target Patient Population
  • Figure 13.3. DARZALEX®: Sales Forecast
  • Figure 13.4. GSK3359609: Target Patient Population
  • Figure 13.5. GSK3359609: Sales Forecast
  • Figure 13.6. RRx-001: Target Patient Population
  • Figure 13.7. RRx-001: Sales Forecast
  • Figure 13.8. SAR650984: Target Patient Population
  • Figure 13.9. SAR650984: Sales Forecast
  • Figure 13.10. MGA271: Target Patient Population
  • Figure 13.11. MGA271: Sales Forecast
  • Figure 13.12. Omburtamab: Target Patient Population
  • Figure 13.13. Omburtamab: Sales Forecast
  • Figure 13.14. AMG557: Target Patient Population
  • Figure 13.15. AMG557: Sales Forecast
  • Figure 13.16. APX005M: Target Patient Population
  • Figure 13.17. APX005M: Sales Forecast
  • Figure 13.18. BI 655064: Target Patient Population
  • Figure 13.19. BI 655064: Sales Forecast
  • Figure 13.20. Dapirolizumab Pegol: Target Patient Population
  • Figure 13.21. Dapirolizumab Pegol: Sales Forecast
  • Figure 13.22. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region(USD Million)
  • Figure 13.23. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, 2020-2030(USD Million)
  • Figure 13.24. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Europe, 2020-2030(USD Million)
  • Figure 13.25. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Asia-Pacific, 2020-2030(USD Million)
  • Figure 13.26. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Rest of the World, 2020-2030(USD Million)
  • Figure 13.27. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication(USD Million)
  • Figure 13.28. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2020-2030(USD Million)
  • Figure 13.29. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2020-2030(USD Million)
  • Figure 13.30. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Hematological Malignancies, 2020-2030(USD Million)
  • Figure 13.31. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2020-2030(USD Million)
  • Figure 13.32. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2020-2030(USD Million)
  • Figure 13.33. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2020-2030(USD Million)
  • Figure 13.34. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-Oncological Indications, 2020-2030(USD Million)
  • Figure 13.35. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint(USD Million)
  • Figure 13.36. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2020-2030(USD Million)
  • Figure 13.37. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030(USD Million)
  • Figure 13.38. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2020-2030(USD Million)
  • Figure 13.39. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2020-2030(USD Million)
  • Figure 13.40. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2020-2030(USD Million)
  • Figure 13.41. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action(USD Million)
  • Figure 13.42. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030(USD Million)
  • Figure 13.43. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2020-2030(USD Million)
  • Figure 13.44. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality(USD Million)
  • Figure 13.45. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Antibody Fragments, 2020-2030(USD Million)
  • Figure 13.46. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibodies, 2020-2030(USD Million)
  • Figure 13.47. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecule Drugs, 2020-2030(USD Million)
  • Figure 13.48. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy(USD Million)
  • Figure 13.49. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030(USD Million)
  • Figure 13.50. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030(USD Million)
  • Figure 13.51. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2020-2030(USD Million)
  • Figure 13.52. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration(USD Million)
  • Figure 13.53. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2020-2030(USD Million)
  • Figure 13.54. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030(USD Million)
  • Figure 13.55. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2020-2030(USD Million)

List Of Tables

  • Table 3.1. Types of Immunotherapies and Associated Mechanisms of Action
  • Table 4.1. Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
  • Table 4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
  • Table 5.1. Immune Checkpoint Inhibitors for CD47: Development Pipeline
  • Table 5.2. Immune Checkpoint Inhibitors for CD47: List of Therapy Developers
  • Table 6.1. Immune Checkpoint Stimulators for 4-1BB: Development Pipeline
  • Table 6.2. Immune Checkpoint Stimulators: List of Therapy Developers
  • Table 8.1. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Companies Profiled
  • Table 8.2. Bristol- Myers Squibb: Company Snapshot
  • Table 8.3. Drug Profile: BMS-986016
  • Table 8.4. Drug Profile: BMS-986015
  • Table 8.5. Drug Profile: BMS-986213
  • Table 8.6. Drug Profile: BMS-986156
  • Table 8.7. Drug Profile: BMS-986207
  • Table 8.8. Drug Profile: BMS-986179
  • Table 8.9. Drug Profile: BMS-986258
  • Table 8.10. Drug Profile: BMS-663513
  • Table 8.11. Drug Profile: BMS-986205
  • Table 8.12. Drug Profile: BMS-986178
  • Table 8.13. Drug Profile: BMS-936561
  • Table 8.14. Recent Developments and Future Outlook
  • Table 8.15. Eli Lilly: Company Snapshot
  • Table 8.16. Drug Profile: LY3321367
  • Table 8.17. Drug Profile: LY3415244
  • Table 8.18. Drug Profile: LY3475070
  • Table 8.19. Drug Profile: LY3381916
  • Table 8.20. Drug Profile: BLTA Agonist
  • Table 8.21. Drug Profile: CD200R Agonist
  • Table 8.22. Recent Developments and Future Outlook
  • Table 8.23. GlaxoSmithKline: Company Snapshot
  • Table 8.24. Drug Profile: GSK3359609
  • Table 8.25. Drug Profile: GSK2831781
  • Table 8.26. Drug Profile: GSK3174998
  • Table 8.27. Drug Profile: TSR-022
  • Table 8.28. Drug Profile: TSR-033
  • Table 8.29. Drug Profile: TSR-075
  • Table 8.30. Recent Developments and Future Outlook
  • Table 8.31. Novartis: Company Snapshot
  • Table 8.32. Drug Profile: CDZ173
  • Table 8.33. Drug Profile: CFZ533
  • Table 8.34. Drug Profile: MBG453
  • Table 8.35. Drug Profile: LAG525
  • Table 8.36. Drug Profile: GWN323
  • Table 8.37. Drug Profile: NZV930
  • Table 8.38. Recent Developments and Future Outlook
  • Table 8.39. XOMA: Company Snapshot
  • Table 8.40. Drug Profile: PBF-509
  • Table 8.41. Drug Profile: PBF-677
  • Table 8.42. Drug Profile: PBF-999
  • Table 8.43. Recent Developments and Future Outlook
  • Table 9.1. Grant Analysis: Multivariate Grant Attractiveness Analysis
  • Table 10.1. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
  • Table 13.1. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Forecasted Drug Candidates
  • Table 16.1. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Phase of Development
  • Table 16.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Immune Checkpoint
  • Table 16.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Mechanism of Action
  • Table 16.4. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Modality
  • Table 16.5. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Route of Administration
  • Table 16.6. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Disease Indication
  • Table 16.7. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Area
  • Table 16.8. Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Type of Therapy
  • Table 16.9. Funnel Representation: Distribution by Phase of Development, Mechanism of Action and Type of Therapy
  • Table 16.10. Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Year of Establishment
  • Table 16.11. Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Company Size and Geographical Location
  • Table 16.12. Leading Developer Companies: Distribution by Number of Pipeline Therapies
  • Table 16.13. Immune Checkpoint Inhibitors for CD47: Distribution by Phase of Development
  • Table 16.14. Immune Checkpoint Inhibitors for CD47: Distribution by Therapeutic Modality
  • Table 16.15. Immune Checkpoint Inhibitors for CD47: Distribution by Route of Administration
  • Table 16.16. Immune Checkpoint Inhibitors for CD47: Distribution by Target Disease Indication
  • Table 16.17. Immune Checkpoint Inhibitors for CD47: Distribution by Type of Therapy
  • Table 16.18. Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Year of Establishment
  • Table 16.19. Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Company Size and Geographical Location
  • Table 16.20. Leading Developers: Distribution by Number of Pipeline Therapies for CD47
  • Table 16.21. Immune Checkpoint Stimulators for 4-1BB: Distribution by Phase of Development
  • Table 16.22. Immune Checkpoint Stimulators for 4-1BB: Distribution by Therapeutic Modality
  • Table 16.23. Immune Checkpoint Stimulators for 4-1BB: Distribution by Route of Administration
  • Table 16.24. Immune Checkpoint Stimulators for 4-1BB: Distribution by Target Disease Indication
  • Table 16.25. Immune Checkpoint Stimulators for 4-1BB: Distribution by Type of Therapy
  • Table 16.26. Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Year of Establishment
  • Table 16.27. Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Company Size and Geographical Location
  • Table 16.28. Leading Developers: Distribution by Number of Therapies for 4-1BB
  • Table 16.29. Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
  • Table 16.30. Clinical Trial Analysis: Distribution by Trial Phase
  • Table 16.31. Clinical Trial Analysis: Distribution by Trial Status
  • Table 16.32. Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Table 16.33. Clinical Trial Analysis: Distribution by Study Design
  • Table 16.34. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 16.35. Leading Industry Sponsors: Distribution by Number of Registered Trials
  • Table 16.36. Clinical Trial Analysis: Distribution by Target Immune Checkpoint
  • Table 16.37. Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Table 16.38. Popular Interventions: Distribution by Number of Registered Trials
  • Table 16.39. Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Table 16.40. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
  • Table 16.41. Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Table 16.42. Bristol-Myers Squibb: Annual Revenues, 2014- 9M 2019(USD Billion)
  • Table 16.43. Eli Lilly: Annual Revenues, 2014- 3M 2019(USD Billion)
  • Table 16.44. GlaxoSmithKline: Annual Revenues, 2014-2019(USD Billion)
  • Table 16.45. Novartis: Annual Revenues, 2014-6M 2019(USD Billion)
  • Table 16.46. XOMA: Annual Revenues, 2014-9M 2019(USD Million)
  • Table 16.47. Grant Analysis: Distribution by Year of Grant Award, 2016-2019
  • Table 16.48. Grant Analysis: Distribution by Amount Awarded(USD Million), 2016-2019
  • Table 16.49. Grant Analysis: Distribution by Administering Institute Center
  • Table 16.50. Grant Analysis: Distribution by Funding Institute Center
  • Table 16.51. Grant Analysis: Distribution by Support Period
  • Table 16.52. Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Table 16.53. Grant Analysis: Distribution by Type of Grant Application
  • Table 16.54. Grant Analysis: Distribution by Purpose of Grant Award
  • Table 16.55. Grant Analysis: Distribution by Grant Mechanism
  • Table 16.56. Popular Target Immune Checkpoints: Distribution by Number of Grants
  • Table 16.57. Grant Analysis: Distribution of Grant Amount Awarded by Target Immune Checkpoints
  • Table 16.58. Grant Analysis: Distribution by Study Section Involved
  • Table 16.59. Grant Analysis: Distribution by Types of Recipient Organizations
  • Table 16.60. Popular Recipient Organizations: Distribution by Number of Grants
  • Table 16.61. Prominent Program Officers: Distribution by Number of Grants
  • Table 16.62. Grant Analysis: Distribution by Recipient Organizations
  • Table 16.63. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
  • Table 16.64. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 16.65. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2020.
  • Table 16.66. Partnerships and Collaborations: Distribution by Target Immune Checkpoint
  • Table 16.67. Partnerships and Collaborations: Distribution by Year of Partnership and Target Immune Checkpoint
  • Table 16.68. Partnerships and Collaborations: Distribution Type of Partnership and Target Immune Checkpoint
  • Table 16.69. Partnerships and Collaborations: Distribution by Type of Partnership and Target Disease Indication
  • Table 16.70. Partnerships and Collaborations: Distribution by Year and Type of Partner
  • Table 16.71. Most Active Players: Distribution by Number of Partnerships
  • Table 16.72. Partnership and Collaborations: Regional Distribution
  • Table 16.73. Big Pharma Initiatives: Distribution by Number of Initiatives
  • Table 16.74. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030(USD Million)
  • Table 16.75. DARZALEX®: Sales Forecast
  • Table 16.76. GSK3359609: Sales Forecast
  • Table 16.77. RRx-001: Sales Forecast
  • Table 16.78. SAR650984: Sales Forecast
  • Table 16.79. MGA271: Sales Forecast
  • Table 16.80. Omburtamab: Sales Forecast
  • Table 16.81. AMG557: Sales Forecast
  • Table 16.82. APX005M: Sales Forecast
  • Table 16.83. BI 655064: Sales Forecast
  • Table 16.84. Dapirolizumab Pegol: Sales Forecast
  • Table 16.85. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region(USD Million)
  • Table 16.86. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, 2020-2030(USD Million)
  • Table 16.87. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Europe, 2020-2030(USD Million)
  • Table 16.88. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Asia-Pacific, 2020-2030(USD Million)
  • Table 16.89. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Rest of the World, 2020-2030(USD Million)
  • Table 16.90. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication(USD Million)
  • Table 16.91. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2020-2030(USD Million)
  • Table 16.92. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2020-2030(USD Million)
  • Table 16.93. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Hematological Malignancies, 2020-2030(USD Million)
  • Table 16.94. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2020-2030(USD Million)
  • Table 16.95. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2020-2030(USD Million)
  • Table 16.96. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2020-2030(USD Million)
  • Table 16.97. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-Oncological Indications, 2020-2030(USD Million)
  • Table 16.98. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint(USD Million)
  • Table 16.99v Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2020-2030(USD Million)
  • Table 16.100. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030(USD Million)
  • Table 16.101. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2020-2030(USD Million)
  • Table 16.102. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2020-2030(USD Million)
  • Table 16.103. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2020-2030(USD Million)
  • Table 16.104. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action(USD Million)
  • Table 16.105. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030(USD Million)
  • Table 16.106. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2020-2030(USD Million)
  • Table 16.107. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality(USD Million)
  • Table 16.108. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Antibody Fragments, 2020-2030(USD Million)
  • Table 16.109. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibodies, 2020-2030(USD Million)
  • Table 16.110. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecule Drugs, 2020-2030(USD Million)
  • Table 16.111. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy(USD Million)
  • Table 16.112. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030(USD Million)
  • Table 16.113. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030(USD Million)
  • Table 16.114. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2020-2030(USD Million)
  • Table 16.115. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration(USD Million)
  • Table 16.116. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2020-2030(USD Million)
  • Table 16.117. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030(USD Million)
  • Table 16.118. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2020-2030(USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. AbbVie
  • 2. AbClon
  • 3. Abeome
  • 4. ABL Bio
  • 5. Abpro
  • 6. Acerta Pharma
  • 7. Acrus Biosciences
  • 8. Actinium Pharmaceuticals
  • 9. Adaptive Biotechnologies
  • 10. AdoRx Therapeutics
  • 11. Aduro Biotech
  • 12. Advaxis
  • 13. Agenus
  • 14. Agios Pharmaceuticals
  • 15. Alexion Pharmaceuticals
  • 16. Allergan
  • 17. Alligator Bioscience
  • 18. Alpine Immune Sciences
  • 19. ALX Oncology
  • 20. Amgen
  • 21. Angel Therapeutics
  • 22. Anvil Biosciences(The company has been acquired)
  • 23. Apexigen
  • 24. Apogenix
  • 25. Aptevo Therapeutics
  • 26. Arch Oncology
  • 27. Arcus Biosciences
  • 28. ArQule
  • 29. Astellas Pharma
  • 30. Astex Pharmaceuticals
  • 31. AstraZeneca
  • 32. Atridia
  • 33. Aurigene Discovery Technologies
  • 34. Avacta Life Sciences
  • 35. Bach BioSciences
  • 36. BeiGene
  • 37. BinDeBio Group
  • 38. BIOCAD
  • 39. Biodextris
  • 40. BioNTech
  • 41. Bio-Techne
  • 42. Black Belt Therapeutics
  • 43. BliNK Biomedical
  • 44. bluebird bio
  • 45. Boehringer Ingelheim
  • 46. Boston Medical Center
  • 47. Brigham and Women's Hospital
  • 48. Bristol-Myers Squibb
  • 49. Calithera Biosciences
  • 50. CALIXAR
  • 51. CASI Pharmaceuticals
  • 52. Catalent Biologics
  • 53. Celgene
  • 54. Celldex Therapeutics
  • 55. Center for Applied Medical Research
  • 56. Centrose
  • 57. Checkpoint Therapeutics
  • 58. China National Biotec Group
  • 59. CleveXel Pharma
  • 60. Columbia University Irving Medical Center
  • 61. Compass Therapeutics
  • 62. Compugen
  • 63. Corvus Pharmaceuticals
  • 64. Crescendo Biologics
  • 65. CStone Pharmaceuticals
  • 66. Curis
  • 67. D5Pharma
  • 68. Daiichi Sankyo
  • 69. Distributed Bio
  • 70. DNAtrix
  • 71. Domain Therapeutics
  • 72. Dova Pharmaceuticals
  • 73. Dualogics
  • 74. Eisai
  • 75. Eli Lilly
  • 76. Elpiscience Biopharma
  • 77. ELSALYS BIOTECH
  • 78. EMulate Therapeutics
  • 79. EpicentRx
  • 80. FF Pharmaceuticals
  • 81. Five Prime Therapeutics
  • 82. Forty Seven
  • 83. Fred Hutchinson Cancer Research Center
  • 84. F-star
  • 85. Gateway Biologics
  • 86. Genentech
  • 87. Genmab
  • 88. Genomics Medicine Ireland
  • 89. Genosco
  • 90. GigaGen
  • 91. Gilead Sciences
  • 92. Glaxosmithkline
  • 93. Glenmark
  • 94. Glycotope
  • 95. Hanmi Pharmaceutical
  • 96. HanX Biopharmaceuticals
  • 97. Heat Biologics
  • 98. Hrain Biotechnology
  • 99. Hummingbird Bioscience
  • 100. IGM Biosciences
  • 101. I-Mab Biopharma
  • 102. Immatics
  • 103. ImmuneOncia Therapeutics
  • 104. ImmuneOnco Biopharmaceuticals
  • 105. ImmuNext
  • 106. Impetis Biosciences
  • 107. Incyte
  • 108. Inhibrx
  • 109. Innate Pharma
  • 110. Innovent Biologics
  • 111. Institute for Research in Biomedicine
  • 112. InteRNA Technologies
  • 113. International Myeloma Foundation
  • 114. IO Biotech
  • 115. iOnctura
  • 116. iTeos Therapeutics
  • 117. Janssen Pharmaceuticals
  • 118. Jiangxi Qingfeng Pharmaceutical
  • 119. JN Biosciences
  • 120. Johns Hopkins University
  • 121. Johnson & Johnson
  • 122. Juventas Cell Therapy
  • 123. KAHR Medical
  • 124. Kiniksa Pharmaceuticals
  • 125. Kite Pharma
  • 126. Kleo Pharmaceuticals
  • 127. Kymab
  • 128. Kyowa Hakko Kirin
  • 129. Leap Therapeutics
  • 130. LG Chem
  • 131. LifeArc
  • 132. Lynkcell
  • 133. Macrocure
  • 134. MacroGenics
  • 135. Marino Biotechnology
  • 136. Massachusetts General Hospital
  • 137. MedImmune
  • 138. Merck
  • 139. Merus
  • 140. Moderna
  • 141. Molecular Partners
  • 142. Molecular Templates
  • 143. Momenta Pharmaceuticals
  • 144. Morphiex
  • 145. MorphoSys
  • 146. Mount Sinai Innovation Partners
  • 147. Nanjing Chia Tai Tianqing
  • 148. National Cancer Institute
  • 149. National Heart, Lung, and Blood Institute
  • 150. National Institute of Allergy and Infectious Diseases
  • 151. National Institute of Biomedical Imaging and Bioengineering
  • 152. National Institute of Dental and Craniofacial Research
  • 153. National Institute of Diabetes and Digestive and Kidney Diseases
  • 154. National Institute of Neurological Disorders
  • 155. NavarraBiomed-Biomedical Research Centre
  • 156. Navigen
  • 157. Neon Therapeutics
  • 158. NewLink Genetics
  • 159. NextCure
  • 160. Novartis
  • 161. Novimmune
  • 162. Numab Therapeutics
  • 163. Ogeda
  • 164. OncoArendi Therapeutics
  • 165. Oncotelic
  • 166. Ono Pharmaceutical
  • 167. ORIC Pharmaceuticals
  • 168. OSE Immunotherapeutics
  • 169. Palobiofarma
  • 170. Pandion Therapeutics
  • 171. Paradigm Shift Therapeutics
  • 172. Parker Institute for Cancer Immunotherapy
  • 173. Pascal Biosciences
  • 174. Peloton Therapeutics
  • 175. PeptiDream
  • 176. PersonGen BioTherapeutics(Suzhou)
  • 177. Pfizer
  • 178. PharmAbcine
  • 179. Pieris Pharmaceuticals
  • 180. Pinze Lifetechnology
  • 181. Potenza Therapeutics
  • 182. PsiOxus Therapeutics
  • 183. Roche
  • 184. Rubius Therapeutics
  • 185. Sanofi
  • 186. Sanquin
  • 187. Seattle Genetics
  • 188. Shanghai GeneChem
  • 189. Shattuck Labs
  • 190. Shire
  • 191. Sorrento Therapeutics
  • 192. Stanford University
  • 193. Surface Oncology
  • 194. Sutro Biopharma
  • 195. Swedish Orphan Biovitrum
  • 196. Symphogen
  • 197. Synthon International Holding
  • 198. Syros Pharmaceuticals
  • 199. Takeda Pharmaceutical
  • 200. Tarus Therapeutics
  • 201. Tempest Therapeutics
  • 202. TESARO
  • 203. TG Therapeutics
  • 204. The University of Texas MD Anderson Cancer Center
  • 205. Tottori University
  • 206. TRACON Pharmaceuticals
  • 207. Trellis Biosciences
  • 208. TRIGR Therapeutics
  • 209. Trillium Therapeutics
  • 210. Tsinghua University
  • 211. Union Stem Cell & Gene Engineering
  • 212. University of California San Francisco
  • 213. University of California, Los Angeles
  • 214. University of California, San Diego
  • 215. University of Minnesota
  • 216. Vall d'Hebron Institute of Oncology
  • 217. Valo Therapeutics
  • 218. Viela Bio
  • 219. ViraTherapeutics
  • 220. Vivoryon Therapeutics
  • 221. Washington University
  • 222. Waterstone Hanxbio
  • 223. Xencor
  • 224. XOMA
  • 225. Y-Biologics
  • 226. Yale Cancer Center
  • 227. Yale University
  • 228. Y-mAbs Therapeutics
  • 229. Yuhan Pharmaceuticals
  • 230. Zai Lab
  • 231. Zymeworks
Back to Top